FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912684592> ?p ?o ?g. }

• W2912684592 endingPage "989" @default.
• W2912684592 startingPage "982" @default.
• W2912684592 abstract "Abstract Background Infliximab pharmacokinetics in steroid-refractory [SR] ulcerative colitis [UC] suggest a need for higher dosing, but data concerning efficacy of intensification in this setting are lacking in children and inconsistent overall. Methods Paediatric patients [N = 125] treated with infliximab for SR or steroid-dependent UC were retrospectively reviewed. Outcomes [clinical response and remission, colectomy, mucosal healing, safety] with standard vs intensified induction [mean induction dose ≥7 mg/kg or interval ≤5 weeks between doses 1 and 3] were compared. Results Among 125 patients [median age 14 years, median UC duration 0.7 years, 74 SR], 73 [58%] received standard induction and 52 [42%] received intensified induction. Overall, 73 [58%] achieved remission (judged by physician global assessment [PGA] and paediatric UC activity index [PUCAI]≤10]. Among patients in remission, 7 [10%] experienced secondary loss of response by a median of 0.7 [IQR 0.4–1.0] years. Of the 74 SR patients, 17 [23%] underwent colectomy, and of the 51 steroid-dependent patients, 12 [24%] underwent colectomy. Intensified induction in SR patients was associated with a higher chance of remission (hazard ratio [HR] 3.2, p = 0.02) and a lower chance of colectomy [HR 0.4, p = 0.05], but did not improve outcomes in steroid-dependent patients. During follow-up, 46/73 [63%] patients in remission had regimen individualization, with similar rates of return to standard dosing after 1 year between those with initial intensified or standard induction. Follow-up endoscopy, performed in 35/73 patients in remission, demonstrated mucosal healing for 66%. Adverse events were rare, despite use of intensified regimens. Conclusions These data suggest a benefit from intensified infliximab induction specifically among children with steroid-refractory UC. Prospective studies comparing dosing regimens and incorporating therapeutic drug monitoring should be undertaken." @default.
• W2912684592 created "2019-02-21" @default.
• W2912684592 creator A5001607216 @default.
• W2912684592 creator A5009290511 @default.
• W2912684592 creator A5020538296 @default.
• W2912684592 creator A5035802660 @default.
• W2912684592 creator A5046943455 @default.
• W2912684592 creator A5056035453 @default.
• W2912684592 creator A5067346461 @default.
• W2912684592 creator A5067402350 @default.
• W2912684592 date "2019-01-23" @default.
• W2912684592 modified "2023-10-15" @default.
• W2912684592 title "Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis" @default.
• W2912684592 cites W1468100171 @default.
• W2912684592 cites W1874557034 @default.
• W2912684592 cites W1981017999 @default.
• W2912684592 cites W1989167852 @default.
• W2912684592 cites W2043780895 @default.
• W2912684592 cites W2076620119 @default.
• W2912684592 cites W2079295802 @default.
• W2912684592 cites W2087726829 @default.
• W2912684592 cites W2095161324 @default.
• W2912684592 cites W2103755206 @default.
• W2912684592 cites W2107045048 @default.
• W2912684592 cites W2109158444 @default.
• W2912684592 cites W2114266978 @default.
• W2912684592 cites W2115487750 @default.
• W2912684592 cites W2135936774 @default.
• W2912684592 cites W2144518079 @default.
• W2912684592 cites W2146963207 @default.
• W2912684592 cites W2153915282 @default.
• W2912684592 cites W2171297959 @default.
• W2912684592 cites W2171392253 @default.
• W2912684592 cites W2171492921 @default.
• W2912684592 cites W2215920766 @default.
• W2912684592 cites W2265140917 @default.
• W2912684592 cites W2321205867 @default.
• W2912684592 cites W2337476268 @default.
• W2912684592 cites W2574762966 @default.
• W2912684592 cites W2744879509 @default.
• W2912684592 cites W2786209860 @default.
• W2912684592 cites W2791312551 @default.
• W2912684592 cites W2793967284 @default.
• W2912684592 cites W2810925331 @default.
• W2912684592 doi "https://doi.org/10.1093/ecco-jcc/jjz019" @default.
• W2912684592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30715240" @default.
• W2912684592 hasPublicationYear "2019" @default.
• W2912684592 type Work @default.
• W2912684592 sameAs 2912684592 @default.
• W2912684592 citedByCount "23" @default.
• W2912684592 countsByYear W29126845922019 @default.
• W2912684592 countsByYear W29126845922020 @default.
• W2912684592 countsByYear W29126845922021 @default.
• W2912684592 countsByYear W29126845922022 @default.
• W2912684592 countsByYear W29126845922023 @default.
• W2912684592 crossrefType "journal-article" @default.
• W2912684592 hasAuthorship W2912684592A5001607216 @default.
• W2912684592 hasAuthorship W2912684592A5009290511 @default.
• W2912684592 hasAuthorship W2912684592A5020538296 @default.
• W2912684592 hasAuthorship W2912684592A5035802660 @default.
• W2912684592 hasAuthorship W2912684592A5046943455 @default.
• W2912684592 hasAuthorship W2912684592A5056035453 @default.
• W2912684592 hasAuthorship W2912684592A5067346461 @default.
• W2912684592 hasAuthorship W2912684592A5067402350 @default.
• W2912684592 hasConcept C121332964 @default.
• W2912684592 hasConcept C126322002 @default.
• W2912684592 hasConcept C141071460 @default.
• W2912684592 hasConcept C142424586 @default.
• W2912684592 hasConcept C17991360 @default.
• W2912684592 hasConcept C207103383 @default.
• W2912684592 hasConcept C2776667177 @default.
• W2912684592 hasConcept C2777138892 @default.
• W2912684592 hasConcept C2779134260 @default.
• W2912684592 hasConcept C2780479503 @default.
• W2912684592 hasConcept C2781413609 @default.
• W2912684592 hasConcept C44249647 @default.
• W2912684592 hasConcept C71924100 @default.
• W2912684592 hasConcept C87355193 @default.
• W2912684592 hasConcept C90924648 @default.
• W2912684592 hasConceptScore W2912684592C121332964 @default.
• W2912684592 hasConceptScore W2912684592C126322002 @default.
• W2912684592 hasConceptScore W2912684592C141071460 @default.
• W2912684592 hasConceptScore W2912684592C142424586 @default.
• W2912684592 hasConceptScore W2912684592C17991360 @default.
• W2912684592 hasConceptScore W2912684592C207103383 @default.
• W2912684592 hasConceptScore W2912684592C2776667177 @default.
• W2912684592 hasConceptScore W2912684592C2777138892 @default.
• W2912684592 hasConceptScore W2912684592C2779134260 @default.
• W2912684592 hasConceptScore W2912684592C2780479503 @default.
• W2912684592 hasConceptScore W2912684592C2781413609 @default.
• W2912684592 hasConceptScore W2912684592C44249647 @default.
• W2912684592 hasConceptScore W2912684592C71924100 @default.
• W2912684592 hasConceptScore W2912684592C87355193 @default.
• W2912684592 hasConceptScore W2912684592C90924648 @default.
• W2912684592 hasIssue "8" @default.
• W2912684592 hasLocation W29126845921 @default.
• W2912684592 hasLocation W29126845922 @default.
• W2912684592 hasOpenAccess W2912684592 @default.

• next